

Dong M Shin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6341113/dong-m-shin-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

246
papers

26,585
citations

64
h-index

161
g-index

250
ext. papers

29,166
ext. citations

8.4
avg, IF

6.75
L-index

#	Paper	IF	Citations
246	Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) Staging for Selected and Nonselected Oropharyngeal Squamous Cell Carcinomas.. <i>Oncologist</i> , 2022 , 27, 48-56	5.7	1
245	A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer. <i>Cancers</i> , 2022 , 14, 2639	6.6	1
244	The omission of intentional primary site radiation following transoral robotic surgery in 59 patients: No local-regional failures. <i>Head and Neck</i> , 2021 , 44, 382	4.2	0
243	Socioeconomic Factors Influence the Impact of Tumor HPV Status on Outcome of Patients With Oropharyngeal Squamous Cell Carcinoma. <i>JCO Oncology Practice</i> , 2021 , 17, e313-e322	2.3	2
242	Combination of resveratrol and green tea epigallocatechin gallate induces synergistic apoptosis and inhibits tumor growth in head and neck cancer models. <i>Oncology Reports</i> , 2021 , 45,	3.5	2
241	Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study. <i>Cancer</i> , 2021 , 127, 3361-3371	6.4	3
240	Combinatorial approaches targeting the EGFR family and c-Met in SCCHN. <i>Oral Oncology</i> , 2021 , 112, 105074	4.4	5
239	Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population. <i>Laryngoscope</i> , 2021 , 131, E921-E928	3.6	5
238	The role of the gut microbiome in cancer-related fatigue: pilot study on epigenetic mechanisms. <i>Supportive Care in Cancer</i> , 2021 , 29, 3173-3182	3.9	12
237	Plasma Metabolic Phenotypes of HPV-Associated versus Smoking-Associated Head and Neck Cancer and Patient Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1858-1866	4	
236	Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1. <i>Nature Communications</i> , 2021 , 12, 4960	17.4	7
235	Functional HPV-specific PD-1 stem-like CD8 T cells in head and neck cancer. <i>Nature</i> , 2021 , 597, 279-284	50.4	28
234	Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 111, 157-167	4	2
233	Demographic and Socioeconomic Factors Associated With Metastases at Presentation in HPV-Related Squamous Cell Carcinoma of the Head and Neck: An NCDB Analysis. <i>JCO Oncology Practice</i> , 2020 , 16, e476-e487	2.3	1
232	Outcomes and Predictive Value of Post-adjuvant Therapy PET/CT for Locally Advanced Oral Squamous Cell Carcinoma. <i>Laryngoscope</i> , 2020 , 130, E850-E857	3.6	0
231	Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer. <i>Vaccines</i> , 2020 , 8,	5.3	6
230	Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. <i>Clinical Cancer Research</i> , 2020 , 26, 5860-5868	12.9	4

229	Gut Microbiome Associated with the Psychoneurological Symptom Cluster in Patients with Head and Neck Cancers. <i>Cancers</i> , 2020 , 12,	6.6	16
228	Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. <i>Head and Neck</i> , 2019 , 41, 1490-1498	4.2	14
227	Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. <i>Journal of Clinical Investigation</i> , 2019 , 129, 2431-2445	15.9	16
226	Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4110-4123	15.9	11
225	Small Cell and Squamous Cell Carcinomas of the Head and Neck: Comparing Incidence and Survival Trends Based on Surveillance, Epidemiology, and End Results (SEER) Data. <i>Oncologist</i> , 2019 , 24, 1562-1569	5.7	11
224	Interleukin-6/STAT3 Signaling is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2019 , 13, 304-312	3.3	6
223	Prognostic implications of peritumoral vasculature in head and neck cancer. <i>Cancer Medicine</i> , 2019 , 8, 147-154	4.8	11
222	Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx. <i>Cancer</i> , 2019 , 125, 704-711	6.4	11
221	Visualization of the Cellular Uptake and Trafficking of DNA Origami Nanostructures in Cancer Cells. <i>Journal of the American Chemical Society</i> , 2018 , 140, 2478-2484	16.4	131
220	A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 710-716	6.1	20
219	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. <i>Oral Oncology</i> , 2018 , 77, 92-97	4.4	6
218	Orthopedia homeobox is preferentially expressed in typical carcinoids of the lung. <i>Cancer Cytopathology</i> , 2018 , 126, 236-242	3.9	12
217	Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. <i>Cancer</i> , 2018 , 124, 84-94	6.4	12
216	MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. <i>Cancer Cell</i> , 2018 , 34, 315-330.e7	24.3	43
215	Associations among human papillomavirus, inflammation, and fatigue in patients with head and neck cancer. <i>Cancer</i> , 2018 , 124, 3163-3170	6.4	18
214	Single-cell compressibility quantification for assessing metastatic potential of cancer cells through multi-frequency acoustophoresis. <i>Microfluidics and Nanofluidics</i> , 2018 , 22, 1	2.8	7
213	Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018 , 82, 83-90	4.4	15
212	Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin. <i>Clinical Cancer Research</i> , 2018 , 24, 858-869	12.9	16

211	Differential regulation of NF- κ B and IRF target genes as they relate to fatigue in patients with head and neck cancer. <i>Brain, Behavior, and Immunity</i> , 2018 , 74, 291-295	16.6	11
210	HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models. <i>Clinical Cancer Research</i> , 2017 , 23, 677-686	12.9	46
209	and Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 729-738	6.1	13
208	Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. <i>Cancer</i> , 2017 , 123, 3476-3485	6.4	27
207	Modulation of Bax and mTOR for Cancer Therapeutics. <i>Cancer Research</i> , 2017 , 77, 3001-3012	10.1	17
206	Efficacy, long-term toxicity, and mechanistic studies of gold nanorods photothermal therapy of cancer in xenograft mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E3110-E3118	11.5	176
205	Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. <i>Clinical Lung Cancer</i> , 2017 , 18, 286-292	4.9	34
204	Association of Cytoplasmic CXCR4 With Loss of Epithelial Marker and Activation of ERK1/2 and AKT Signaling Pathways in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, e203-e210	4.9	11
203	High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. <i>Molecular Cancer Research</i> , 2017 , 15, 179-188	6.6	14
202	Systemic Delivery of Bc12-Targeting siRNA by DNA Nanoparticles Suppresses Cancer Cell Growth. <i>Angewandte Chemie - International Edition</i> , 2017 , 56, 16023-16027	16.4	79
201	Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2017 , 39, 2433-2443	4.2	4
200	Systemic Delivery of Bc12-Targeting siRNA by DNA Nanoparticles Suppresses Cancer Cell Growth. <i>Angewandte Chemie</i> , 2017 , 129, 16239-16243	3.6	13
199	Multiple biological functions of Twist1 in various cancers. <i>Oncotarget</i> , 2017 , 8, 20380-20393	3.3	69
198	Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. <i>Oncotarget</i> , 2017 , 8, 59008-59022	3.3	7
197	Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. <i>Supportive Care in Cancer</i> , 2016 , 24, 1789-93	3.9	27
196	Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 209-16	13.4	89
195	Fatigue is associated with inflammation in patients with head and neck cancer before and after intensity-modulated radiation therapy. <i>Brain, Behavior, and Immunity</i> , 2016 , 52, 145-152	16.6	42
194	Development of Late Toxicities in Patients with Oral Tongue Cancer Treated with Surgical Resection and Adjuvant Radiation Therapy. <i>Frontiers in Oncology</i> , 2016 , 6, 272	5.3	2

193	Biomarker quantification by multiplexed quantum dot technology for predicting lymph node metastasis and prognosis in head and neck cancer. <i>Oncotarget</i> , 2016 , 7, 44676-44685	3.3	9
192	Antitumor Activity of 2,9-Di-Sec-Butyl-1,10-Phenanthroline. <i>PLoS ONE</i> , 2016 , 11, e0168450	3.7	3
191	Anticancer activity of drug conjugates in head and neck cancer cells. <i>Frontiers in Bioscience - Elite</i> , 2016 , 8, 358-69	1.6	3
190	A novel prediction model for human papillomavirus-associated oropharyngeal squamous cell carcinoma using p16 and subcellular E-catenin expression. <i>Journal of Oral Pathology and Medicine</i> , 2016 , 45, 399-408	3.3	4
189	Clinical outcomes in elderly patients with human papillomavirus-positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapy. <i>Head and Neck</i> , 2016 , 38, 846-51	4.2	11
188	The Challenges of Laryngeal Preservation-Is It the Systemic Agent or the Proper Sequence of Therapy?. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016 , 142, 849-50	3.9	2
187	Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation. <i>European Journal of Cancer</i> , 2016 , 65, 21-32	7.5	20
186	Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. <i>Seminars in Cancer Biology</i> , 2015 , 35 Suppl, S55-S77	12.7	67
185	Racial disparities in squamous cell carcinoma of the oral tongue among women: a SEER data analysis. <i>Oral Oncology</i> , 2015 , 51, 586-92	4.4	39
184	FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway. <i>Cancer Letters</i> , 2015 , 363, 166-75	9.9	11
183	Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. <i>Lung Cancer</i> , 2015 , 88, 80-4	5.9	16
182	Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2015 , 20, 986-95	5.4	17
181	Targeting HER (ERBB) signaling in head and neck cancer: An essential update. <i>Molecular Aspects of Medicine</i> , 2015 , 45, 74-86	16.7	16
180	HPV16 E6 and E7 proteins induce a chronic oxidative stress response via NOX2 that causes genomic instability and increased susceptibility to DNA damage in head and neck cancer cells. <i>Carcinogenesis</i> , 2015 , 36, 1397-406	4.6	50
179	Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma. <i>Cancer</i> , 2015 , 121, 3600-11	6.4	34
178	Curcumin induces apoptosis of upper aerodigestive tract cancer cells by targeting multiple pathways. <i>PLoS ONE</i> , 2015 , 10, e0124218	3.7	30
177	Canine spontaneous head and neck squamous cell carcinomas represent their human counterparts at the molecular level. <i>PLoS Genetics</i> , 2015 , 11, e1005277	6	26
176	CCR 20th Anniversary Commentary: Prospects and Challenges of Therapeutic Nanoparticles in Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 4499-501	12.9	3

175	Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. <i>Cancer Cell</i> , 2015 , 27, 257-70	24.3	194
174	Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review. <i>Oral Oncology</i> , 2014 , 50, 888-94	4.4	15
173	Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. <i>Clinical Cancer Research</i> , 2014 , 20, 5041-51	12.9	24
172	Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity. <i>Cancer Prevention Research</i> , 2014 , 7, 65-73	3.2	99
171	Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. <i>Cancer</i> , 2014 , 120, 1394-400	6.4	23
170	Procedure for developing linear and Bayesian classification models based on immunosensor measurements. <i>Sensors and Actuators B: Chemical</i> , 2014 , 190, 165-170	8.5	6
169	Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 1826-36	6.1	51
168	Targeted iron-oxide nanoparticle for photodynamic therapy and imaging of head and neck cancer. <i>ACS Nano</i> , 2014 , 8, 6620-32	16.7	102
167	Epidemiology of head and neck squamous cell cancer among HIV-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 65, 603-10	3.1	45
166	Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2014 , 120, 3940-51	6.4	39
165	Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the Warburg effect. <i>Journal of Biological Chemistry</i> , 2014 , 289, 26533-26541	5.4	50
164	Tyr-94 phosphorylation inhibits pyruvate dehydrogenase phosphatase 1 and promotes tumor growth. <i>Journal of Biological Chemistry</i> , 2014 , 289, 21413-22	5.4	39
163	Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase Ib and pharmacokinetic study. <i>Cancer Prevention Research</i> , 2014 , 7, 283-91	3.2	52
162	Patients' perceptions of complementary and alternative medicine in head and neck cancer: a qualitative, pilot study with clinical implications. <i>Complementary Therapies in Clinical Practice</i> , 2014 , 20, 213-8	3.5	10
161	Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck. <i>Head and Neck Pathology</i> , 2014 , 8, 66-72	3.3	26
160	Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis. <i>PLoS ONE</i> , 2014 , 9, e86369	3.7	33
159	Synthetic curcumin analog UBS109 inhibits the growth of head and neck squamous cell carcinoma xenografts. <i>Current Cancer Drug Targets</i> , 2014 , 14, 380-93	2.8	11
158	Expression of tumor biomarkers in HIV-infected patients with head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6086-6086	2.2	

157	Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2013 , 35, 443-53	4.2	27
156	Laryngeal tumor volume as a predictor for thyroid cartilage penetration. <i>Head and Neck</i> , 2013 , 35, 426-30	4.2	11
155	Interruption of nuclear localization of ATBF1 during the histopathologic progression of head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2013 , 35, 1007-14	4.2	7
154	Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. <i>Cancer</i> , 2013 , 119, 1503-11	6.4	11
153	Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009. <i>Cancer</i> , 2013 , 119, 2602-10	6.4	125
152	Antitumor properties of five-coordinate gold(III) complexes bearing substituted polypyridyl ligands. <i>Journal of Inorganic Biochemistry</i> , 2013 , 128, 68-76	4.2	21
151	Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. <i>Clinical Cancer Research</i> , 2013 , 19, 1244-56	12.9	50
150	Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. <i>Nature Communications</i> , 2013 , 4, 1790	17.4	58
149	Molecular Aspects of Cancer Prevention by Green Tea: An Overview 2013 , 751-766		
148	Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer. <i>Oncologist</i> , 2013 , 18, 1262-9	5.7	9
147	p90 RSK2 mediates antiankist signals by both transcription-dependent and -independent mechanisms. <i>Molecular and Cellular Biology</i> , 2013 , 33, 2574-85	4.8	20
146	RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. <i>Clinical Cancer Research</i> , 2013 , 19, 3416-28	12.9	77
145	The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis. <i>Journal of Biological Chemistry</i> , 2013 , 288, 32528-32538	5.4	39
144	Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition. <i>Journal of Biological Chemistry</i> , 2013 , 288, 1469-79	5.4	30
143	Prognostic impact of Fas-associated death domain, a key component in death receptor signaling, is dependent on the presence of lymph node metastasis in head and neck squamous cell carcinoma. <i>Cancer Biology and Therapy</i> , 2013 , 14, 365-9	4.6	15
142	New perspectives of curcumin in cancer prevention. <i>Cancer Prevention Research</i> , 2013 , 6, 387-400	3.2	174
141	Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 369-72	8.9	35
140	Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer. <i>PLoS ONE</i> , 2013 , 8, e74670	3.7	59

139	Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. <i>Journal of Controlled Release</i> , 2012 , 159, 384-92	11.7	63
138	Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. <i>Cancer</i> , 2012 , 118, 164-72	6.4	29
137	Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 577-90	3.5	6
136	Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. <i>Cancer Cell</i> , 2012 , 22, 585-600	24.3	268
135	Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts. <i>Integrative Biology (United Kingdom)</i> , 2012 , 4, 633-40	3.7	30
134	Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer. <i>European Journal of Cancer</i> , 2012 , 48, 1682-91	7.5	37
133	HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases?. <i>Head and Neck Pathology</i> , 2012 , 6, 336-44	3.3	48
132	A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment. <i>International Journal of Cancer</i> , 2012 , 131, 956-69	7.5	29
131	Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data. <i>Cancer</i> , 2012 , 118, 4444-51	6.4	194
130	Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. <i>Cancer</i> , 2012 , 118, 4694-705	6.4	34
129	The pivotal role of integrin $\alpha 5$ in metastasis of head and neck squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2012 , 18, 4589-99	12.9	35
128	Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. <i>ACS Nano</i> , 2011 , 5, 9480-93	16.7	115
127	Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. <i>Cancer Research</i> , 2011 , 71, 1526-32	10.1	292
126	Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR. <i>Molecular Cancer</i> , 2011 , 10, 116	42.1	35
125	Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. <i>Cancer</i> , 2011 , 117, 4049-59	6.4	14
124	Patterns of extralaryngeal spread of laryngeal cancer: thyroid cartilage penetration occurs in a minority of patients with extralaryngeal spread of laryngeal squamous cell cancers. <i>Cancer</i> , 2011 , 117, 5047-51	6.4	21
123	A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. <i>ACS Nano</i> , 2011 , 5, 6184-94	16.7	115
122	Tumor cytotoxicity of 5,6-dimethyl-1,10-phenanthroline and its corresponding gold(III) complex. <i>Journal of Inorganic Biochemistry</i> , 2011 , 105, 663-8	4.2	53

121	Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis. <i>Oncology</i> , 2011 , 81, 12-20	3.6	83
120	Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. <i>Journal of Biological Chemistry</i> , 2010 , 285, 34557-65	5.4	91
119	Chemopreventive potential of natural compounds in head and neck cancer. <i>Nutrition and Cancer</i> , 2010 , 62, 973-87	2.8	49
118	Chemoprevention of head and neck cancer with green tea polyphenols. <i>Cancer Prevention Research</i> , 2010 , 3, 900-9	3.2	65
117	Prognostic accuracy of computed tomography findings for patients with laryngeal cancer undergoing laryngectomy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2318-22	2.2	75
116	The medicinal chemistry of theragnostics, multimodality imaging and applications of nanotechnology in cancer. <i>Current Topics in Medicinal Chemistry</i> , 2010 , 10, 1211-26	3	37
115	Targeted delivery of paclitaxel to tumor cells: synthesis and in vitro evaluation. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 3127-32	8.3	29
114	c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL. <i>Molecular Cancer</i> , 2010 , 9, 315	42.1	27
113	Restoration of p53 functions protects cells from concanavalin A-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 471-9	6.1	15
112	A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. <i>ACS Nano</i> , 2010 , 4, 5887-96	16.7	356
111	Comparison and optimization of multiplexed quantum dot-based immunohistofluorescence. <i>Nano Research</i> , 2010 , 3, 61-68	10	22
110	Cancer prevention with natural compounds. <i>Seminars in Oncology</i> , 2010 , 37, 258-81	5.5	350
109	Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. <i>Cancer</i> , 2010 , 116, 3903-9	6.4	35
108	p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. <i>Journal of Clinical Investigation</i> , 2010 , 120, 1165-77	15.9	114
107	Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact. <i>PLoS ONE</i> , 2010 , 5, e12178	3.7	33
106	caGrid-Enabled caBIG Silver Level Compatible Head and Neck Cancer Tissue Database System. <i>Open Medical Informatics Journal</i> , 2010 , 4, 171-8	1	
105	Advances of cancer therapy by nanotechnology. <i>Cancer Research and Treatment</i> , 2009 , 41, 1-11	5.2	140
104	Oral cancer prevention advances with a translational trial of green tea. <i>Cancer Prevention Research</i> , 2009 , 2, 919-21	3.2	9

103	Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. <i>Cancer Prevention Research</i> , 2009 , 2, 823-9	3.2	35
102	Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1976-82	2.2	35
101	Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1235-42	2.2	52
100	Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 599-604	2.2	85
99	Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. <i>Cancer Prevention Research</i> , 2009 , 2, 538-45	3.2	48
98	HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. <i>ACS Nano</i> , 2009 , 3, 3165-74	16.7	142
97	Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug. <i>Head and Neck</i> , 2009 , 31, 475-81	4.2	42
96	Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer. <i>Head and Neck</i> , 2009 , 31, 1263-73	4.2	3
95	Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: a retrospective single-institution analysis. <i>Head and Neck</i> , 2009 , 31, 1447-55	4.2	13
94	Perspectives for cancer prevention with natural compounds. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2712-25	2.5	395
93	Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells. <i>Nanotechnology</i> , 2009 , 20, 225102	3.4	24
92	Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells. <i>Journal of Receptor and Signal Transduction Research</i> , 2009 , 29, 182-94	2.6	13
91	Nanoparticle therapeutics: an emerging treatment modality for cancer 2009 , 239-250		34
90	Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009 , 32, 15-9	2.7	3
89	In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. <i>Nature Biotechnology</i> , 2008 , 26, 83-90	44.5	1945
88	Nanoparticle therapeutics: an emerging treatment modality for cancer. <i>Nature Reviews Drug Discovery</i> , 2008 , 7, 771-82	64.1	3332
87	Application of nanotechnology in cancer therapy and imaging. <i>Ca-A Cancer Journal for Clinicians</i> , 2008 , 58, 97-110	220.7	453
86	Recent advances in head and neck cancer. <i>New England Journal of Medicine</i> , 2008 , 359, 1143-54	59.2	703

85	Head and neck cancer chemoprevention gets a shot in the arm. <i>Journal of Clinical Oncology</i> , 2008 , 26, 345-7	2.2	20
84	Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. <i>International Journal of Nanomedicine</i> , 2008 , 3, 311-21	7.3	263
83	Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation. <i>Cancer</i> , 2008 , 113, 97-107	6.4	59
82	Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. <i>International Journal of Cancer</i> , 2008 , 123, 1005-14	7.5	86
81	Concurrent platinum-based chemotherapy and simultaneous modulated accelerated radiation therapy for locally advanced squamous cell carcinoma of the tongue base. <i>Head and Neck</i> , 2008 , 30, 327-35	4.2	32
80	Therapeutic nanoparticles for drug delivery in cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 1310-6	12.9	2208
79	Nanotechnology for targeted cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 833-7	3.5	146
78	Down-regulation of S100A2 in lymph node metastases of head and neck cancer. <i>Head and Neck</i> , 2007 , 29, 236-43	4.2	17
77	Induction of cell cycle arrest and apoptosis by a combined treatment with 13-cis-retinoic acid, interferon-alpha2a, and alpha-tocopherol in squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2007 , 29, 351-61	4.2	9
76	Moving toward bioadjuvant approaches to head and neck cancer prevention. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 69, S132-5	4	4
75	Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. <i>New England Journal of Medicine</i> , 2007 , 357, 1705-15	59.2	1268
74	Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. <i>Cancer Research</i> , 2007 , 67, 10538-45	10.1	119
73	Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 3006-14	12.9	28
72	CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. <i>Cancer Research</i> , 2007 , 67, 7518-24	10.1	112
71	Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. <i>Clinical Cancer Research</i> , 2007 , 13, 3015-23	12.9	24
70	Targeting angiogenesis in head and neck cancer. <i>Current Cancer Drug Targets</i> , 2007 , 7, 643-9	2.8	9
69	Current status and future perspectives of chemoprevention in head and neck cancer. <i>Current Cancer Drug Targets</i> , 2007 , 7, 623-32	2.8	18
68	Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 441-50	9.7	188

67	Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer—a plan to move forward. <i>Clinical Cancer Research</i> , 2006 , 12, 3661-97	12.9	235
66	Fenretinide activity in retinoid-resistant oral leukoplakia. <i>Clinical Cancer Research</i> , 2006 , 12, 3109-14	12.9	43
65	Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 1909-17	6.1	591
64	Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. <i>New England Journal of Medicine</i> , 2006 , 354, 567-78	59.2	3964
63	Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis. <i>Clinical and Experimental Metastasis</i> , 2006 , 23, 209-22	4.7	35
62	Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. <i>Oncology</i> , 2006 , 20, 153-61; discussion 162, 166, 169 passim	1.8	13
61	Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. <i>JAMA Otolaryngology</i> , 2005 , 131, 304-7		36
60	A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 717-24	4	20
59	Neoadjuvant chemotherapy for squamous cell carcinoma of the oral tongue in young adults: a case series. <i>Head and Neck</i> , 2005 , 27, 748-56	4.2	21
58	Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 55, 354-360	3.5	16
57	Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3495-501	2.2	76
56	Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. <i>Clinical Cancer Research</i> , 2005 , 11, 6261-9	12.9	112
55	Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 3846-53	12.9	65
54	Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5578-87	2.2	337
53	Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1448-55	6.1	76
52	Emerging drugs for head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 2004 , 9, 91-104	3.7	3
51	Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. <i>Clinical Cancer Research</i> , 2004 , 10, 5930-9	12.9	124
50	Correlation of protease-activated receptor-1 with differentiation markers in squamous cell carcinoma of the head and neck and its implication in lymph node metastasis. <i>Clinical Cancer Research</i> , 2004 , 10, 8451-9	12.9	27

49	Advances in chemoprevention of head and neck cancer. <i>Oncologist</i> , 2004 , 9, 302-11	5.7	28
48	Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. <i>Cancer</i> , 2004 , 100, 2240-5	6.4	7
47	Prevention of head and neck cancer: current status and future prospects. <i>Current Problems in Cancer</i> , 2004 , 28, 265-86	2.3	11
46	Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. <i>Clinical Cancer Research</i> , 2004 , 10, 2968-76	12.9	72
45	Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. <i>Lung Cancer</i> , 2004 , 44, 369-79	5.9	237
44	Emerging drugs for head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 2004 , 9, 91-104	3.7	1
43	Advances in the management of malignant mesothelioma. <i>Current Oncology Reports</i> , 2003 , 5, 334-41	6.3	13
42	Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma. <i>Cancer</i> , 2003 , 99, 233-9	6.4	29
41	Prevention of radiation-induced oral cavity mucositis by plasmid/liposome delivery of the human manganese superoxide dismutase (SOD2) transgene. <i>Radiation Research</i> , 2003 , 159, 361-70	3.1	91
40	Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 367-80	3.5	70
39	Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 198-205	9.7	84
38	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. <i>Cancer</i> , 2002 , 94, 1593-611	6.4	391
37	The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. <i>Cancer</i> , 2002 , 95, 340-53	6.4	29
36	Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2002 , 95, 322-30	6.4	48
35	Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. <i>Cancer</i> , 2001 , 91, 1316-23	6.4	64
34	Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2001 , 92, 2364-73	6.4	43
33	Recent advances in the management of squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2001 , 1, 99-110	3.5	5
32	Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1096-104	2.2	123

31	Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2626-37	2.2	104
30	Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3010-7	2.2	101
29	Phase I trial of oral green tea extract in adult patients with solid tumors. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1830-8	2.2	198
28	Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer. <i>Current Opinion in Oncology</i> , 2001 , 13, 168-75	4.2	20
27	Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). <i>Cancer Gene Therapy</i> , 2000 , 7, 530-6	5.4	59
26	Phase II study of intravenous Doxil in malignant pleural mesothelioma. <i>Investigational New Drugs</i> , 2000 , 18, 243-5	4.3	30
25	Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2309-15	2.2	45
24	Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2390-5	2.2	47
23	Phase I study of paclitaxel administered by ten-day continuous infusion. <i>Investigational New Drugs</i> , 1998 , 16, 237-43	4.3	6
22	Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998 , 40, 331-6	4	6
21	Phase II trial of recombinant IFN-alpha2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer. <i>Journal of Interferon and Cytokine Research</i> , 1998 , 18, 241-5	3.5	6
20	A multidisciplinary approach to therapy for unresectable malignant thymoma. <i>Annals of Internal Medicine</i> , 1998 , 129, 100-4	8	107
19	Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma. <i>Cancer</i> , 1998 , 82, 301-8	6.4	13
18	Detection of chromosome instability of tissue fields at risk: In situ hybridization. <i>Journal of Cellular Biochemistry</i> , 1996 , 63, 57-62	4.7	30
17	Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis. <i>Cancer and Metastasis Reviews</i> , 1996 , 15, 53-76	9.6	40
16	Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995 , 33, 179-82	4	173
15	Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995 , 31, 807-11	4	13
14	Molecular phenotyping of head and neck cancer. <i>Cancer Treatment and Research</i> , 1995 , 74, 17-42	3.5	1

13	Biomarkers in chemoprevention for upper aerodigestive tract tumors. <i>Yonsei Medical Journal</i> , 1994 , 35, 113-31	3	3
12	Phase II clinical trial of didemnin B in previously treated small cell lung cancer. <i>Investigational New Drugs</i> , 1994 , 12, 243-9	4.3	31
11	Thymoma. A retrospective study of 87 cases. <i>Cancer</i> , 1994 , 73, 2491-8	6.4	85
10	Activation of ribosomal protein S2 gene expression in a hamster model of chemically induced oral carcinogenesis. <i>Carcinogenesis</i> , 1993 , 14, 163-6	4.6	13
9	Early genetic changes during upper aerodigestive tract tumorigenesis. <i>Journal of Cellular Biochemistry</i> , 1993 , 17F, 233-6	4.7	25
8	Implantation metastasis of carcinoma after percutaneous fine-needle aspiration biopsy. <i>Chest</i> , 1992 , 102, 313-5	5.3	76
7	Thymoma: treatment and prognosis. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992 , 23, 1037-43	4	85
6	Elevated expression of the ribosomal protein S2 gene in human tumors. <i>Molecular Carcinogenesis</i> , 1992 , 5, 219-31	5	54
5	Renal salt wasting in patients treated with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 1992 , 7, 118-21	2.5	17
4	Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancer. <i>Cancer</i> , 1991 , 68, 959-64	6.4	12
3	Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting. <i>Cancer Chemotherapy and Pharmacology</i> , 1991 , 29, 145-9	3.5	42
2	Reduction to homozygosity at the SIS/PDGF-2 locus in human mesenchymal tumors. <i>Biochemical and Biophysical Research Communications</i> , 1988 , 155, 692-9	3.4	2
1	Designing and Conducting Phase III Studies1		